Abdelaal, A., Sohal, I.S., Iyer, S., Reddy, S., Barker, A., Low, P.S., Kasinski, A.L. (2024, anticipated) Ligand-mediated delivery of miR-34a for the treatment of prostate cancer. Molecular Therapy – Nucleic Acids (under revision)

Abdelaal, A.M., Sohal, I.S., Iyers, S., Sudarshan, K., Lanman, N.A., Kothandaraman, H., Low, P.S., Kasinski, A.L. (2023) A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor eff Oncogene (2023). 

Hasan H. and Kasinski, A.L. (2023) Tracking microRNA release into extracellular vesicles using flow cytometry. Journal of Visualized Experiments.

Sohal, I.S. and Kasinski, A.L. (2023) Extracellular vesicle biogenesis in cancer. Frontiers in Oncology. Vol 13 16 June 2023

Agredo A.M. and Kasinski, A.L. (2023) Histone 4 lysine 20 trimethylation: A key epigenetic regulator in chromatin structure and disease.  Frontiers in Genetics. Aug 21;14:1243395

Li WJ, Wang Y, Liu X, Wu S, Wang M, Tracz A, Abdelaal AM, Sudarshan K, Puzanov I, Chatta G, Kasinski AL, Tang DG. (2023) Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises. bioRxiv. 2023 Nov 25:2023.11.25.568612. doi: 10.1101/2023.11.25.568612. Preprint.


*Pal, A.S., *Agredo, A., Lanman, N.A., Son, J., Sohal, I.S., Bains, M., Li, C., Clingerman, J., Gates, K., Kasinski A.L. (2021) Loss of KMT5C promotes EGFR inhibitor resistance in NSCLC through upregulation of MET and LIN01510. Cancer Research 2022 Apr 15;82(8):1534-1547

*Husan H., *Sohal, I., *Soto, Z., Byappanahalli, A., Humphry, S., Kubo, H., Kitdumrongthum, S., Copeland, S., Tian, F., Chairoungdua, A., and Kasinski, A.L. (2022) Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic epithelial cells. Scientific Reports 2022 Jan 19;12(1):972

Pal, A.S., Agredo, A., Kasinski A.L. (2022) In-cell western protocol for semi-high-throughput screening of single clones. Bio-Protocol 2022 Aug 20;12(16):e4489


Abdelaal, A.M., and Kasinski, A.L. (2021) Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases. Nucleic Acids Research Cancer, Jul 2-;3(3):zcabb030

Li,  W., Wang, Y., Liu, R., Kasinski, A.L., Shen, H., Slack, F.J., and Tang, D.G. (2021) MicroRNA-34a (miR-34a): Potent Tumor Suppressor, Cancer Stem Cell Inhibitor and Potential Anti-Cancer Therapeutic, Frontiers in Cell and Developmental Biology, 9:640587.

Elshafie N.O., do Nascimento N.C., Lichti N.I., Kasinski A.L., Childress M.O., Dos Santos A.P. (2021) MicroRNA Biomarkers in Canine Diffuse Large B-Cell Lymphoma. Veterinary Pathology

Pal, A. S., Bains, M., Agredo, A, and Kasinski A.L. (2021) Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer. Biochemical Pharmacology


Elshafie N.O., do Nascimento N.C., Lichti N.I., Kasinski A.L., Childress M.O., Dos Santos A.P. (2020) MicroRNA Biomarkers in Canine Diffuse Large B-Cell Lymphoma. Veterinary Pathology

Li, C., and Kasinski A.L. (2020) In Vivo Cancer-Based Functional Genomics. Trends in Cancer

Pal, A.S., Agredo, A., Lanman, N.A.,  Clingerman, J., Gates, K., and Kasinski, A.L. (2020) Loss of SUV420H2 promotes EGFR inhibitor resistance in NSCLC through upregulation of MET via LINC01510. bioRxiv


Kasinski, A.L. (2019) Combatting PDAC with two tumor-targeting small RNAs. Oncotarget

Orellana E.A., Li, C., Lisevick, A., and Kasinski, A.L. (2019) Identification and validation of miRNAs that synergize with miR-34a – a basis for combinatorial miRNA therapeutics. Cell Cycle 2019 Aug;18(15):1798-1811

Orellana, E.A., Rangasamy, R., Abdelaal, A.H., Tenneti, S., Myoung, S., Low, P.S., Kasinski, A.L. (2019) Enhancing microRNA activity through increased endosomal release mediated by nigericin. Molecular Therapy: Nucleic Acids, Vol 16, 505-518

Myoung, S., and Kasinski, A.L. (2019) MicroRNAs in Diseases and Disorders – Emerging Therapeutic Targets. Chapter 14: Strategies for safe and targeted delivery of microRNA therapeutics. Royal Society of Chemistry. 386-415 May 2019


Rangasamy, L., Chelvam, V., Kanduluru, A.K., Srinivasarao, M., Bandara, A.N., You, F., Orellana, E., Kasinski, A.L., Low, P.S. (2018) New mechanism for release of endosomal contents: osmotic lysis via nigericin-mediated K+/H+ exchange.  Bioconjugate Chemistry 2018 Feb 15

Zhou, W., Pal, A.S., Yi-Hui Hsu, A., Gurol, T., Zhu, Z., Wirbisky-Hershberger, S.E., Freeman, J., Kasinski, A.L., Deng, Q. (2017) MicroRNA-223 suppresses the canonical NF-kB pathway in basal keratinocytes to dampen neutrophilic inflammation. Cell Reports 2018 Feb 13;22(7):1810-1823


Orellana, E.A., and Kasinski A.L. (2017) No vehicle, no problem.  Oncotarget.

Pal, A.S., and Kasinski, A.L. (2017) Animal modles to study microRNA function. Advances in Cancer Research. Vol 135 pp53-118

Orellana, E.A., Tenneti, S., Rangasamy, R., Low, P.S., Kasinski, A.L. (2017) FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer. Science Translational Medicine. August 2, 2017


Orellana, E.A., and Kasinski, A.L. (2016) Sulforhodamine B (SRB) assay in cell culture to investigate cell proliferation. Bio-Protocols. September 2016 


Orellana E.A., and Kasinski, A.L. (2015) MicroRNAs in cancer: A historical perspective on the path from discovery to therapy. Cancers 7(3), 1388-1405

Humphrey, S. and Kasinski, A.L. (2015) RNA guided CRISPR-Cas Technologies for Genome Scale Investigation of Disease Processes. Journal of Hematology and Oncology. 2015, 8 :31 (2 April 2015)


Kasinski, A.L., Kelner, K., Stahlhut, C., Orellana, E., Zhao, J., Shimer, E., Dysart, S., Chen, X., Bader, A.G., Slack, F.J. (2014) A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene, September 2014

Kasinski, A.L., Boss, J., Khuri, F.R., Fu, H. (2014) Transcriptional regulation of YWHAZ, the gene encoding 14-3-3 zeta. PLoS-ONE, April, 2014


*Kasinski, A.L., *Slack, F.J. (2013) Small RNAs deliver a blow to ovarian cancer. * co-corresponding authors. Cancer Discovery, November 2013 3;1220

*Kasinski, A.L., Slack, F.J. (2013) Generation of mouse lung epithelial cells. Bio-Protocols. * corresponding author Bio Protocol article

Puckett, M.C., Goldman, E.H., Cockrell, L.M., Huang, B., Kasinki, A.L., Du, Y., Wang, C., Lin, A., Ichijo, H., Khuri, F.R., and Fu, H. (2013) Integration of the Apoptosis signal-regulating kinase 1-mediated stress signaling with the Akt/PKB-IkB kinase cascade. Mol Cell Biol 2013 Jun;33(11):2252-9


Kasinski, A.L., Slack, F.J. (2012) miRNA-34 prevents cancer initiation and progression in a therapeutically resistant Kras and p53-induced mouse model of lung adenocarcinoma. Cancer Research, Sept; 72, 5576-5587

Kasinski, A.L., Slack, F.J. (2012) Arresting the culprit: targeted antagomir delivery to sequester oncogenic miR-221 in HCC. Molecular Therapy – Nucleic Acids, March; 1(3):12


Kasinski, A.L., Slack, F.J. (2011) Therapeutic microRNAs en route to the clinic: progress in validating and targeting miRNAs for cancer therapy. Nature Reviews Cancer, Nov 24; 11(12):849-64

Kim, M., Kasinski, A.L., Slack, F.J. (2011) MicroRNA therapeutics in pre-clinical cancer models. Lancet Oncology, Apr;12(4):319-321

Kasinski, A.L., Fu, H. (2011) 14-3-3 zeta.  UCSD-Nature Molecule Pages. (doi:10.1038/mp.a000060.01)


Kasinski, A.L., Slack, F.J. (2010) Potential microRNA therapies targeting Ras, NFkB and p53 signaling.  Current Opinion in Molecular Therapeutics, Apr; 12(2):147-57

Earlier studies

Kasinski, A.L., Du, Y., Thomas, S., Zhao, J., Sun, S.Y., Khuri, F.R., Wang, C.Y., Shoji, M., Sun, A., Snyder, J., Liotta, D., Fu, H. (2008) Inhibition of IKK-NFkB signaling pathway by EF24, a novel monoketone analogue of curcumin.  Molecular Pharmacology Sep; 74(3):654-61

Park, H.R., Cockrell, L.M., Du, Y., Kasinski, A., Havel, J., Zhao, J., Reyes-Turcu, F., Wilkinson, K., Fu, H. (2008) Methods for Protein-Protein Interactions, Molecular Biomethods Handbook 2nd Edition.

Kasinski, A., Doering, C.B. and Danner, D.J. (2004) Leucine toxicity in a neuronal cell model with inhibited branched chain amino acid catabolism. Molecular Brain Research 122: 180-7.

Danner, D.J., Muller, E.A., Kasinski, A. (2004) The complexity of single gene disorders: Lessons from maple syrup urine disease and thiamin responsiveness.  Thiamine:  catalytic mechanisms and role in normal and disease states.  Ed by M.S. Patel and F. Jordan, Academic Press.

Nellis, M.M., Kasinski, A., Carlson, M., Allen, R., Schaefer, A.M., Schwartz, E.M., Danner, D.J. (2003) Relationship of causative genetic mutations in maple syrup urin disease with their clinical expression.  Mol. Genet. Metab. 80: 189-95

Nellis, M.M., Doering, C.B., Kasinski, A. and Danner, D.J. (2002) Insulin increases branched chain alpha-ketoacid dehydrogenase kinase expression in Clone 9 rat cells. Am J. Physiol. 238: E853-E860.